Evogene (EVGN) is currently trading at $1.56. The bull's view on EVGN stock is cautious optimism due to its strategic shift in Lavie Bio's bio-fungicide pipeline development, retaining technology rights despite Corteva's exit. However, weak financials, including a Q2 2024 EPS miss (-$1.06 vs. -$0.12 expected), and reliance on a $5.5M direct offering for working capital, suggest limited near-term upside.